These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients. Imamura T; Kinugawa K Ann Palliat Med; 2022 Sep; 11(9):2856-2861. PubMed ID: 36096739 [TBL] [Abstract][Full Text] [Related]
24. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure. Du H; Li X; Zhao W; Jiang N J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898 [TBL] [Abstract][Full Text] [Related]
26. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL; Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100 [TBL] [Abstract][Full Text] [Related]
27. Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways. Mapelli M; Mattavelli I; Salvioni E; Bonomi A; Capra N; Palermo P; Banfi C; Paolillo S; Biondi ML; Agostoni P Drugs R D; 2023 Dec; 23(4):397-402. PubMed ID: 37702906 [TBL] [Abstract][Full Text] [Related]
28. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era. Sbolli M; deFilippi C Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511 [TBL] [Abstract][Full Text] [Related]
30. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Masson S; Latini R; Anand IS; Vago T; Angelici L; Barlera S; Missov ED; Clerico A; Tognoni G; Cohn JN; Clin Chem; 2006 Aug; 52(8):1528-38. PubMed ID: 16777915 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related]
32. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760 [TBL] [Abstract][Full Text] [Related]
33. Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial. Myhre PL; Claggett BL; Shah AM; Prescott MF; Ward JH; Fang JC; Mitchell GF; Solomon SD; Desai AS Eur J Heart Fail; 2022 Jul; 24(7):1200-1208. PubMed ID: 35560696 [TBL] [Abstract][Full Text] [Related]
34. BNP molecular forms and processing by the cardiac serine protease corin. Ichiki T; Huntley BK; Burnett JC Adv Clin Chem; 2013; 61():1-31. PubMed ID: 24015598 [TBL] [Abstract][Full Text] [Related]